Published on 21 April 2023
Description:
No dithering, no delay, PharmaTimes is here today! Our tome is all about progress, and the galvanising, inspiring and igniting effect that ‘difference’ so surely brings. Specifically, we will showcase how women are shaping a new culture within industry, yielding a kaleidoscope of perspectives in the process.
Categories:
PharmaTimesPreview:
29 articles from this collection:
Cover
2 - Communique Awards 2023
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: NHS
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-12 - COVER STORY: Funky trainers on a mission
13 - WOMEN IN PHARMA: Bionical Emas
14 - WOMEN IN PHARMA - Axil Integrated Services
15 - WOMEN IN PHARMA: Takeda
16 - FlyPharma Europe
17 - WOMEN IN PHARMA: Aspire Pharma
18 - WOMEN IN PHARMA: Havas Lynx
19 - WOMEN IN PHARMA: Takeda
20-21 - SUSTAINABILITY: Taking our chances
22 - SUSTAINABILITY: New Order
23 - CLIMATE CHANGE: A crisis of. two halves
24-25 - PHARMA COMMS: Listening project
26-27 - CLINICAL TRIALS: Centre of the pharmaverse
28-29 - VACCINES: Empire strikes back
30-31 - CLINICAL TRIALS: The human condition
32-33 - MENTAL HEALTH: A new flame
34-35 - NHS: Borrowed time?
36-37 - Your moves
38 - AI: The bigger picture
39 - Samedan
40 - QIC Dermatology
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.